MedTrace Logo

Postoperative Narcotic Use After Laparoscopic Gynecologic Surgery

NCT04118777 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2021-07-20

No results posted yet for this study

Summary

This will be a prospective, randomized, double blinded placebo-controlled study at Erlanger hospital. Eligible patients who provide consent will be randomized into one of two arms receiving continuous intra-peritoneal local anesthetic with 0.2% Ropivacaine or saline.

Conditions

  • Pelvic Pain
  • Endometriosis
  • Pelvic Prolapse

Interventions

DRUG

Ropivacaine

0.2 % Ropivacaine will be continuously administered intraperitoneally at a rate of 6 mL/hr

Sponsors & Collaborators

  • University of Tennessee, Chattanooga

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2020-06-30
Completion
2020-07-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04118777 on ClinicalTrials.gov